About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Strategic Alliances
  > ABOUT US
  Overview
  Businesses
  Key Facts
  Vision Mission Values
  People
  Quality
  CSR Policy
  EHS Policy
  History
  Awards
  Biocon in Malaysia
  
  
     
 

Biocon in Malaysia

Asia's largest integrated Insulins Manufacturing Facility

Biocon entered Malaysia in 2010 through formation of its subsidiary Biocon Sdn. Bhd., and has set up Asia’s largest integrated insulins manufacturing facility at an investment of over USD 250 million, which is the highest foreign investment in Malaysia’s biotech sector till date. Biocon Malaysia currently employs a team of over 400 people at this state-of-the-art facility. The facility is located within BioXcell, a biotech park in Nusajaya, Johor, which is being promoted by the Malaysian government. This is Biocon’s first overseas biopharma manufacturing and research facility.

The facility manufactures the Drug Substance for Biocon’s range of rh-insulin and insulin analogs as well as Drug Products in vials, cartridges and devices. It has received the cGMP certification from the National Pharmaceutical Control Bureau (NPCB), Malaysia. The rh-Insulin formulations (Brand Name: Insugen®-R, Insugen®-N and Insugen®-30/70) manufactured at this facility have been approved by the Drug Control Authority, Ministry of Health, Malaysia. The product registrations in various emerging markets and regulated markets for rh-insulin and insulin analogs are in progress.

Biocon is also the first Indian company to have made inroads into Japan, one of the world’s most stringent developed markets, with its Insulin Glargine. The company is developing an insulin analogs portfolio for other developed markets like US and Europe. Biocon has also entered into an agreement with Mexico's Laboratorios PiSA to develop and commercialize its rh-Insulin in the US market.

Biocon Limited, India already has approvals in over 60 emerging markets for its rh-Insulin and in over 20 emerging markets for its Insulin Glargine. It is serving the needs of patients with diabetes in several emerging markets in collaboration with its partners in LATAM and Southeast Asia.

The Malaysia facility will further augment Biocon’s capabilities to cater to the global needs of affordable insulin and insulin analogs for patients with diabetes.

Malaysia Unit Walkthrough

Contact:

Biocon Sdn. Bhd.,
No. 1, Jalan Bioteknologi 1,
Kawasan Perindustrian SiLC,
79200 Nusajaya, Johor,
Malaysia

T +607-5600000
E: queries.malaysia@biocon.com

For Job opportunities at Biocon Malaysia,
write to careers.malaysia@biocon.com

 
 
Business Alliance
  Press Releases:
 
   Manipal Education Malaysia and    Biocon Ink Industry Academia    Partnership
   
   Biocon R&D facility in Bio-XCell
 
    
 
 Biocon Malaysia On
/bioconmalaysia
/bioconmalaysia

 

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved